Psychotherapy and Pharmacotherapy in Dissociative Disorders
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00630981|
Recruitment Status : Unknown
Verified April 2009 by Espace Hogan.
Recruitment status was: Active, not recruiting
First Posted : March 7, 2008
Last Update Posted : April 20, 2009
|Condition or disease||Intervention/treatment|
|Dissociative Disorders||Behavioral: Psychotherapy Drug: Pharmacological treatment (Quetiapine and/or Escitalopram)|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||30 participants|
|Official Title:||The Interest of a Specific Combined Treatment (Psychotherapy and Pharmacotherapy) in Patients With Dissociative Disorders|
|Study Start Date :||February 2008|
|Actual Primary Completion Date :||April 2009|
|Estimated Study Completion Date :||July 2009|
Combined psychotherapy and pharmacological treatment
Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.
Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered.
Specific psychotherapy for dissociative disorders
Other Name: Dissociative Disorders
Drug: Pharmacological treatment (Quetiapine and/or Escitalopram)
Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
- To study the efficacy of a specific combined treatment (psychotherapy and pharmacotherapy) on patients with dissociative disorders, in terms of patients with a favorable outcome by means of the DES scale. [ Time Frame: 8 weeks ]
- The relationship between serum lipid levels and depressive symptoms in patients with dissociative disorder during combined treatment. [ Time Frame: 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630981
|Principal Investigator:||Cristian Damsa, MD||HUG|